These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

106 related items for PubMed ID: 10577855

  • 1. Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer.
    Fokkema E, Groen HJ, Bauer J, Uges DR, Weil C, Smith IE.
    J Clin Oncol; 1999 Dec; 17(12):3822-7. PubMed ID: 10577855
    [Abstract] [Full Text] [Related]

  • 2. Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients.
    Fokkema E, de Vries EG, Meijer S, Groen HJ.
    Cancer Chemother Pharmacol; 2000 Dec; 45(1):89-92. PubMed ID: 10647508
    [Abstract] [Full Text] [Related]

  • 3. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days.
    Sessa C, Minoia C, Ronchi A, Zucchetti M, Bauer J, Borner M, de Jong J, Pagani O, Renard J, Weil C, D'Incalci M.
    Ann Oncol; 1998 Dec; 9(12):1315-22. PubMed ID: 9932162
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of a novel platinum analog, SKI 2053R, in patients with previously untreated extensive-stage small-cell lung cancer.
    Zang DY, Lee KH, Lee JS, Lee JH, Kim WK, Kim SH, Kim WD, Kim DS, Kim JH, Kim BS, Cho YB, Kim DK, Kim KH.
    Am J Clin Oncol; 1999 Oct; 22(5):495-8. PubMed ID: 10521066
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S, Buclin T, Lejeune F, Bauer J, Leyvraz S, Decosterd LA.
    Anticancer Res; 2003 Oct; 23(3C):2757-65. PubMed ID: 12926110
    [Abstract] [Full Text] [Related]

  • 6. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.
    Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, Iglesias J.
    J Clin Oncol; 1999 Apr; 17(4):1194. PubMed ID: 10561178
    [Abstract] [Full Text] [Related]

  • 7. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS, Wong H, Zee B, Yu KH, Leung TW, Lee TW, Yim A, Chan AT, Yeo W, Chak K, Johnson P.
    Cancer; 2002 Oct 01; 95(7):1511-9. PubMed ID: 12237920
    [Abstract] [Full Text] [Related]

  • 8. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH, Kim K, Hutson P, DeVore R, Glick J, Stewart J, Johnson D.
    J Clin Oncol; 1996 Aug 01; 14(8):2345-52. PubMed ID: 8708727
    [Abstract] [Full Text] [Related]

  • 9. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA.
    Clin Cancer Res; 1999 Nov 01; 5(11):3419-24. PubMed ID: 10589753
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of carboplatin in previously untreated patients with metastatic small cell lung carcinoma.
    Jacobs RH, Bitran JD, Deutsch M, Hoffman PC, Sinkule J, Purl S, Golomb HM.
    Cancer Treat Rep; 1987 Mar 01; 71(3):311-2. PubMed ID: 3028621
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation.
    Judson I, Cerny T, Epelbaum R, Dunlop D, Smyth J, Schaefer B, Roelvink M, Kaplan S, Hanauske A.
    Ann Oncol; 1997 Jun 01; 8(6):604-6. PubMed ID: 9261531
    [Abstract] [Full Text] [Related]

  • 12. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule.
    Groen HJ, Fokkema E, Biesma B, Kwa B, van Putten JW, Postmus PE, Smit EF.
    J Clin Oncol; 1999 Mar 01; 17(3):927-32. PubMed ID: 10071286
    [Abstract] [Full Text] [Related]

  • 13. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
    Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, Okamoto H, Ogura T, Yokoyama A, Seki N, Asaka-Amano Y, Harada M, Tagawa A, Kunikane H, Yokoba M, Uematsu K, Kuriyama T, Kuroiwa Y, Watanabe K, Thoracic Oncology Research Group Study 0301.
    J Clin Oncol; 2006 Dec 01; 24(34):5448-53. PubMed ID: 17135647
    [Abstract] [Full Text] [Related]

  • 14. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
    Tabata M, Kiura K, Okimoto N, Segawa Y, Shinkai T, Yonei T, Kuyama S, Harita S, Hotta K, Ueoka H, Tanimoto M.
    Cancer Chemother Pharmacol; 2007 Jun 01; 60(1):1-6. PubMed ID: 17393168
    [Abstract] [Full Text] [Related]

  • 15. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
    McKeage MJ, Raynaud F, Ward J, Berry C, O'Dell D, Kelland LR, Murrer B, Santabárabara P, Harrap KR, Judson IR.
    J Clin Oncol; 1997 Jul 01; 15(7):2691-700. PubMed ID: 9215842
    [Abstract] [Full Text] [Related]

  • 16. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients.
    Schmittel A, Knödler M, Hortig P, Schulze K, Thiel E, Keilholz U.
    Lung Cancer; 2007 Jan 01; 55(1):109-13. PubMed ID: 17097191
    [Abstract] [Full Text] [Related]

  • 17. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
    Ardizzoni A, Manegold C, Debruyne C, Gaafar R, Buchholz E, Smit EF, Lianes P, ten Velde G, Bosquee L, Legrand C, Neumaier C, King K, Giuseppe giaccone European organization for research and treatment of cancer (EORTC) lung cancer group.
    Clin Cancer Res; 2003 Jan 01; 9(1):143-50. PubMed ID: 12538462
    [Abstract] [Full Text] [Related]

  • 18. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
    Jett JR, Hatfield AK, Hillman S, Bauman MD, Mailliard JA, Kugler JW, Morton RF, Marks RS, Levitt R.
    Cancer; 2003 May 15; 97(10):2498-503. PubMed ID: 12733149
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer.
    Igawa S, Yamamoto N, Ueda S, Ono A, Nakamura Y, Tsuya A, Murakami H, Endo M, Takahashi T.
    J Thorac Oncol; 2007 Aug 15; 2(8):741-4. PubMed ID: 17762341
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer.
    Eckardt JR, Bentsion DL, Lipatov ON, Polyakov IS, Mackintosh FR, Karlin DA, Baker GS, Breitz HB.
    J Clin Oncol; 2009 Apr 20; 27(12):2046-51. PubMed ID: 19289620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.